
Adcock Ingram reports full-year profit bump
[ad_1] Pharmaceutical producer Adcock Ingram has reported a 24% rise in headline earnings per share (Heps) to 502 cents for the 12 months ended June 2022, boosted by an improved demand for its over-the-counter (OTC) and shopper healthcare merchandise. The JSE-listed group which owns the Panado, Allergex, Citro-Soda, Corenza C







